Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Prostate Cancer
- Thoracic Oncology
- Breast Cancer
- Colon Cancer
- Head and Neck Oncology
- Neoadjuvant Therapy
- Immunotherapy
- Central Nervous System Tumors
Abstract
Citation: Clin Oncol. 2016;1(1):1026.DOI: 10.25107/2474-1663.1026
Emerging Highlights of Antibody Therapy in Oncology
Chen D
Research Institute of Biological Medicine, Yiling Pharmaceutical, China
*Correspondance to: Daohong Chen
PDF Full Text Short Communication | Open Access
Abstract:
As a hallmark of biological medicine, monoclonal antibody (mAb) therapy has evolved into the mainstream treatment in clinical oncology at a relatively fast pace. Whereas a therapeutic mAb was traditionally designed to block signaling molecules driving malignant cell growth or tumor angiogenesis, mAb-based agents are currently explored further in comprehensive contexts of disease biology, including immune checkpoint blockade, antibody-drug conjugates, Fc region modification, bispecific antibody, among others. Herein, this article outlines an updated understanding of these emerging avenues derived from mAb platforms, which are coming up with better innovative medicines to fight cancer.
Keywords:
Cite the Article:
Chen D. Emerging Highlights of Antibody Therapy in Oncology. Clin Oncol. 2016; 1: 1026.